Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia

Study acronym: ALLight
StatusRecruiting
PhasePhase 1/2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 5 months later Apr 28, 2028 → Oct 11, 2028
See other at-risk trials from AstraZeneca

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoints: details revised at 1 of 8 entries Show 6 more changesShow less
    • Primary completion pushed from Apr 28, 2028 to Oct 11, 2028
    • Study completion pushed from Jul 3, 2028 to Jul 18, 2029
    • Study sites: 26 to 27
    • Eligibility criteria expanded, about 70 words
    • Secondary endpoints: details revised at 34 of 34 entries
    • Study description revised
  2. 3 versions Re-verified since May 8, 2026, no change to tracked fieldsv8-v10
  3. Site details revised at 1 of 26 sitesv7
  4. Eligibility criteria shortened, about 6 wordsv6
  5. Site details revised at 9 of 26 sitesv5
Show 3 earlier versionsHide 3 earlier versions
  1. Study sites: 25 to 26v4
  2. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 22 to 25
    • Start date changed from estimate of Oct 31, 2025 to Nov 12, 2025
    v3
  3. Study sites: 17 to 22
    • Eligibility criteria expanded, about 22 words
    • Secondary endpoints: 36 to 34
    v2
  1. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study is intended to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of AZD4512 in patients with relapsed/refractory B-Cell acute lymphoblastic leukemia (r/r B-ALL).
Trial Details
NCT Number NCT07109219
Lead Sponsor AstraZeneca
Collaborators: Fortrea
Conditions
(from sponsor)		 B-cell Acute Lymphoblastic Leukemia (B-ALL)
Related terms Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Enrollment 83 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov